Navigation Links
Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
Date:1/7/2008

SAN DIEGO, Jan. 7 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of oxygen transport agents, announced today that it has started testing its lead product, Hemospan(R), in a Phase II clinical study involving chronic critical limb ischemia (CCLI) patients.

The single-blind, placebo-controlled study at the Karolinska Institute in Stockholm, Sweden is designed to evaluate the safety and efficacy of Hemospan in patients suffering from CCLI, a debilitating condition that results from severely limited blood circulation to the legs. The primary endpoint is tissue oxygenation measured noninvasively.

The goal of this study is to demonstrate that Hemospan can increase oxygen supply to severely compromised tissue, conclusively establishing it as an 'oxygen-carrying plasma expander,'" said Dr. Robert Winslow, Chairman, President and CEO of Sangart.

Hemospan is a hemoglobin-based oxygen transport agent designed to serve as an oxygen therapeutic and as an alternative to blood transfusions. A key property of Hemospan is its high oxygen affinity which results in targeted oxygen delivery to tissues at risk of oxygen deprivation.

About Sangart

Sangart is a privately held biopharmaceutical company focused on the research, development and commercialization of medical products designed for use as oxygen transport agents.

Dr. Robert Winslow, a world-renowned authority in the field of oxygen transport, founded Sangart in 1998. In the two decades prior to founding Sangart, Dr. Winslow and his colleagues studied and defined mechanisms of oxygen transport by cell-free hemoglobin solutions, funded by competitive grants from the National Institutes of Health and the Department of Defense. The counterintuitive discoveries by Dr. Winslow's group on the effective action of oxygen transport agents have been patented and published in numerous scientific articles. From this experience, Sangart's lead product, Hemospan(R), was designed using unique polyethylene glycol conjugation to create a hemoglobin-based product that is intended to serve as an oxygen therapeutic and as an alternative to donated blood.

The key breakthroughs in the development of Hemospan were the understanding of the mechanisms of vasoconstriction caused by cell-free hemoglobin and the development of simplified production methods that are designed to make the final product commercially viable.

Sangart's corporate headquarters are in San Diego, California. To learn more about Sangart, please visit the company's website at http://www.sangart.com.

Media Contact:

Gregory Tiberend or Meghan Feeks

Richard Lewis Communications, Inc.

212-827-0020

gtiberend@rlcinc.com


'/>"/>
SOURCE Sangart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
2. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
3. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
4. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
5. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
6. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
7. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
8. Senesco Technologies Initiates Preclinical Studies for Cancer Target
9. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
10. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
11. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... Aug. 7, 2017  Endo International plc (NASDAQ: ... to resolve virtually all known U.S. mesh product liability ... resolve the known remaining U.S. claims at reasonable values. ... in the fourth quarter of 2017 and continuing through ... second quarter 2017 results, the Company intends to increase ...
(Date:8/2/2017)... , Aug. 2, 2017   Marshall County Hospital in Benton, ... proactively reduce the risk of hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , ... energy to kill deadly pathogens such as C. diff , MRSA, MERS, Ebola and ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:7/31/2017)... 31, 2017 Three Tru-D SmartUVC robots have arrived ... Korea . Tru-D, short for "Total Room Ultraviolet Disinfection," is a ... an environmental services (ES) professional cleans the area with traditional cleaning protocols. ... Tru-D fights germs ... "Although the BAACH has a very ...
Breaking Medicine Technology:
(Date:8/20/2017)... ... August 20, 2017 , ... Are you an adult with gluten intolerance ... you may be interested in participating in a research study that focuses on family ... understand more about the relational aspects of adults who have gluten sensitivities who cohabitate ...
(Date:8/19/2017)... (PRWEB) , ... August 18, 2017 , ... Western University ... health and education to launch the University’s new Center for Innovation on Wednesday, September ... Health Education Center Lecture Hall 1, followed by a technology exhibition from 1 to ...
(Date:8/19/2017)... ... 2017 , ... President Donald Trump signed into law today ... greater public access to over-the-counter (OTC) hearing aids. , The measure enables adults ... being seen by a certified and licensed audiologist. , “The American Speech-Language-Hearing ...
(Date:8/19/2017)... ... August 19, 2017 , ... Curl Keeper® is excited to ... Curl Leaders, Editors’ Choice 2017 Award for the second year in a row. The ... and curlies alike was voted Best Moisturizer for Type 2 Wavies and Best Refresher ...
(Date:8/19/2017)... ... August 19, 2017 , ... Yesterday, the President of the United States ... two sides. There are not two sides to hatred, bigotry, discrimination, and a white ... and the NPEIV stands against all forms of such hatred and discrimination in this ...
Breaking Medicine News(10 mins):